What Sermion 30 Treats: Main Uses and Benefits

---

This medication is used in domains where additional symptomatic support is needed for age-associated circulatory and cognitive conditions. Sermion is commonly used to help with symptoms related to physical discomfort and neurological strain.

It is applied in conditions presenting with recurrent or episodic manifestations, such as chronic symptomatic cognitive and neurosensorial impairment in older adults, peripheral arterial occlusive disease, and Raynaud's syndrome. The medication helps address groups of symptoms that may become intense or disruptive, including deficits in memory and concentration; balance symptoms like vertigo and unsteadiness; and peripheral discomfort such as painful cramping and numbness in the limbs.

Supportive Symptom Management

Sermion is utilized to help manage symptoms that create noticeable physiological strain and interfere with daily functioning. Applied during phases where the patient experiences heightened discomfort, this provides support that helps ease the overall symptom burden, particularly for those dealing with age-related vascular issues.

Quick Fact: Relief for Key Symptom Clusters
Cognitive Domain	Helps manage deficits in memory and vigilance.
Sensory Domain	Supports stability by easing symptoms of dizziness and vertigo.
Peripheral Domain	Assists with the pain and numbness caused by poor circulation.

Regulatory References

1. European Commission on Nicergoline uses

Who can and cannot use Sermion 30 — Official Regulatory Information

The eligibility profile for Sermion 30 (Nicergoline) is strictly defined by regulatory documents, which establish clear restrictions and absolute contraindications.

Contraindicated Populations

Sermion 30 is contraindicated and must not be used in individuals with:

• Known hypersensitivity to Nicergoline or other ergot alkaloids.
• A recent myocardial infarction (heart attack).
• Acute hemorrhage (acute bleeding).
• Severe bradycardia (abnormally slow heart rate) or severe hypotension (very low blood pressure).

Age and Life Stage Restrictions

Population	Eligibility Status	Reason (Official Labeling)
Children	Not Recommended	Safety and efficacy have not been established (due to a lack of clinical data).
Pregnant Women	Not Recommended	Use should be limited to cases where the benefit strongly outweighs the possible risk.
Lactating Women	Not Recommended	Should suspend breastfeeding if treatment is necessary.
Adults/Elderly	Use Established	Approved for symptomatic treatment in these populations.

Condition-Specific Limitations

Use requires caution in patients with compromised renal impairment or hepatic function, as the drug's elimination may be affected. Caution is also advised for patients with hyperuricemia or a history of gout.

Interactions with other medicines and products

Official regulatory information for Nicergoline (Sermion 30) establishes specific interaction patterns based on its pharmacological and metabolic properties. The interaction profile is defined by pharmacodynamic effects on the vascular system and pharmacokinetic modulation of drug metabolism.

Documented Interaction Categories

Category	Description of Official Interaction	Restriction/Classification
Vascular Regulators	Potential for additive effects on blood pressure and heart function.	Co-administration with alpha and beta receptor blockers is advised against or strictly prohibited.
Coagulation System	Increased risk of bleeding or hemorrhage due to Nicergoline's anti-platelet activity.	Caution when co-administering with anticoagulants (e.g., Warfarin) and antiplatelet agents (e.g., Aspirin).
Metabolic Inhibition	Nicergoline is documented as a CYP 1A2 inhibitor, which can decrease the elimination rate of other medicines metabolized by this enzyme.	Caution is advised with other drugs that are primarily CYP 1A2 Substrates.
Herbal/Supplements	Additive vascular effects with agents that also promote vasodilation.	Caution noted for co-administration with products like Ginkgo Biloba.

Population-Specific Notes

The regulatory profile notes that individuals with impaired hepatic or renal function may experience altered Nicergoline clearance and require caution, as these organs are essential for its metabolism and elimination. No mandatory time separation requirements for administration are officially documented.

How Sermion 30 Works

Sermion 30 contains nicergoline, a compound that primarily functions as an antagonist at postsynaptic alpha1-adrenoreceptors located on vascular smooth muscle. This interaction prevents the vasoconstrictive effects of endogenous catecholamines like norepinephrine, leading to a reduction in vascular resistance and resulting in localized vasodilation, particularly within the cerebral circulation.

At the cellular level, nicergoline modulates various metabolic and signaling pathways. It acts as an inhibitor of certain forms of phosphodiesterase (PDE), an enzyme responsible for degrading cyclic AMP (cAMP). Inhibition of PDE leads to an increase in intracellular cAMP concentrations, influencing neuronal second messenger systems.

Furthermore, the compound modulates the utilization of energy substrates within central nervous system tissues. These actions collectively lead to an increase in the rate of cerebral blood flow and an improved metabolic ratio between oxygen supply and glucose demand in the brain parenchyma. Nicergoline also exhibits properties that influence the aggregation of blood platelets.

Sermion (Nicergoline) is administered through several officially approved routes, including oral use via 10 mg or 30 mg tablets, and parenteral use as a 4 mg solution for injection. The parenteral formulation is approved for administration via intravenous (IV) slow infusion, intramuscular (IM), and intra-arterial (IA) routes, all of which require administration by a qualified health professional.

The typical oral regimen is often started at 10 mg taken three times a day (TDS), with established maximum daily doses reaching 60 mg. The tablets must be taken on an empty stomach to ensure optimal systemic uptake. Parenteral dosing for intramuscular use is typically 2 to 4 mg administered twice daily (BD), while IV slow infusion uses 4 to 8 mg. For intravenous use, the injection solution must be diluted in 100 ml of an appropriate isotonic solution, such as saline, before being administered.

Treatment duration is highly variable and often protracted, as therapeutic response may only manifest after a prolonged period of use. Usage restrictions apply to certain populations: the medicine is not recommended for use in patients below 18 years of age. Caution and dose adjustments are necessary for individuals with impaired kidney function. In the event of a missed dose, the patient should skip the missed dose if it is close to the next scheduled dose and must not take a double amount.

Research Evidence / Overview of Studies for Sermion 30

Evidence for Use in Cognitive Decline

Research has explored the compound Sermion (Nicergoline) in contexts associated with cognitive decline. Studies have primarily been conducted as Randomized Controlled Trials (RCTs), where people were randomly assigned to receive either Sermion 30 or a comparison treatment, such as a placebo. This research was evaluated in specific settings examining short-term or episodic symptom patterns.

Studies monitored outcomes reflecting daily functioning, such as changes in standardized scores that measure memory, attention, and activity level. These assessments were applied in studies examining patient-reported experiences. This research provides insight into short-term patterns observed in the studies.

Short-Term Findings: How Studies Measured Effect

Research focused on episodes where symptoms become more noticeable and explored short-term symptom changes within trials lasting a few months (typically up to six months). Researchers mainly examined functional measures and cognitive tests.

Studies report how symptoms evolved in the observed populations, as measured by changes in test scores reflecting memory and thought processes over the study duration. Patient-reported outcomes describing perceived discomfort and general impressions of change was observed in some studies. However, the findings were mixed across various studies and specific endpoints, which is why the evidence quality varies across studies reviewed in meta-analyses.

What is Still Uncertain About Sermion 30 Research

Several areas of uncertainty exist within the evidence base for Sermion 30. Follow-up durations were limited in many primary efficacy studies, meaning there is insufficient data regarding long-term outcomes and the sustained effects over several years. Additionally, comparative evidence is lacking in terms of direct, head-to-head trials against newer pharmacological treatments that are currently used for similar cognitive conditions. The findings describe group patterns, not personal outcomes, and the heterogeneity across the study designs means that certainty remains low for some aspects of the research.

Common questions about Sermion 30 (FAQ)

---

Q: Is Sermion 30 the same kind of medicine as aspirin?

A: Sermion 30 contains the active ingredient Nicergoline, which is officially classified as a Peripheral Vasodilator and Cerebral Activator. This means its primary function is related to widening blood vessels and supporting brain cell activity. Aspirin belongs to a distinct and different pharmacological class of medications, making their core functions different based on official classifications.

---

Q: How quickly should someone expect to notice the effects of Sermion 30?

A: Official product information indicates that the therapeutic response may only manifest after a prolonged period of use. Due to this factor, the required duration of treatment is often protracted. Clinical studies examining changes in symptoms typically observed outcomes over periods of a few months.

---

Q: Is Sermion 30 an official treatment for poor circulation?

A: The general purpose of the medicine is described as enhancing local microcirculation and cellular metabolic efficiency. The active compound is studied for its use in relation to circulatory disorders, but the specific, officially approved regulatory indications for its use can vary between countries.

---

Q: Can Sermion 30 be taken indefinitely, or is it a short-term treatment?

A: The required duration of treatment is highly variable and often described as protracted. Official regulatory documents include a warning that the risk of certain serious effects, specifically fibrotic reactions, has been linked to prolonged exposure or lengthy treatment duration, suggesting a protracted or lengthy treatment duration is allowed under official guidance.

---

Q: What is the risk of Sermion 30 interacting with common supplements like vitamin D or fish oil?

A: Official regulatory information advises caution when Sermion 30 is co-administered with other agents that promote vasodilation, such as the herbal supplement Ginkgo Biloba. However, the regulatory documentation does not provide specific data or warnings related to common nutritional supplements like Vitamin D or Fish Oil.

---

Q: Is Sermion 30 available without a prescription in some countries?

A: In the region governed by the primary regulatory source, Sermion 30 is officially designated as a prescription-only pharmaceutical preparation. Whether a product is available over the counter can vary greatly depending on the specific country or region and its local drug classification.

---

Q: Can Sermion 30 affect a person's mood or cause anxiety?

A: The documented side effects that affect the central nervous system include common reactions like headache, dizziness, sleepiness, and insomnia. Official regulatory documents list these specific effects. General mood changes or anxiety are not specifically featured among the commonly listed adverse effects in the official documentation.

---

Q: How does the time of day a person takes Sermion 30 affect its action?

A: To ensure optimal uptake into the body, the tablets must be taken on an empty stomach. While this food-related instruction is noted, official documents do not provide mandatory time separation requirements or specific advice regarding how the time of day affects its action.

---

Q: Is there a generic version of Sermion 30 available?

A: Sermion is a brand name for the active ingredient Nicergoline. The active ingredient itself is widely available in different international markets. Official drug databases indicate that Nicergoline is sold under multiple generic names in various international markets, alongside the original Sermion brand.

---

Q: How is Sermion 30 eliminated from the body?

A: The drug's metabolism and subsequent elimination from the body depend on both kidney and liver function. Elimination occurs primarily through the urine and to a minor extent through feces. This process is often completed within three to four days after the last dose.

---

Q: What should a person do if they suspect an allergic reaction to Sermion 30?

A: An allergic reaction, or hypersensitivity to Nicergoline or other related ergot derivatives, is listed as an absolute contraindication for use. If a patient experiences a reaction, official guidance emphasizes the necessity of seeking instructions from a qualified health professional.

---

Q: How does Sermion 30 differ from a simple dietary supplement?

A: Sermion 30 is classified as a prescription-only pharmaceutical preparation. Its active component, Nicergoline, is a semisynthetic ergot derivative. Dietary supplements are regulated under different legal and quality control frameworks than prescription medicines.

---

Q: Can Sermion 30 affect performance when driving or operating machinery?

A: Due to its actions on the nervous and vascular systems, Sermion 30 has documented side effects that include dizziness and sleepiness. Official regulatory guidance generally includes a warning that if patients experience these symptoms, they should use caution and avoid activities like driving or operating complex machinery.

---

Q: Do patients generally tolerate Sermion 30 well?

A: Official documents list known adverse effects by the affected body system, such as psychoneurologic and gastrointestinal disorders. However, the regulatory information explicitly states that the frequency of many of these reactions is often not known, which prevents official sources from making a general statement on overall patient tolerability.

---

Q: Can Sermion 30 be used by patients who have heart conditions?

A: The medicine is strictly contraindicated, meaning it must not be used, in patients who have certain serious heart conditions. These include a recent myocardial infarction (heart attack), or conditions causing severe bradycardia (a very slow heart rate) and severe hypotension (very low blood pressure).

---

Q: Is the use of Sermion 30 supported by official health organizations?

A: Official health organizations classify Nicergoline based on its function. For example, the World Health Organization (WHO) assigns Nicergoline an ATC code that officially classifies it as a Peripheral Vasodilator.

---

Q: What happens if a person accidentally takes too much Sermion 30?

A: Official regulatory documents for the product contain a dedicated section on overdose. This information details the expected symptoms that may occur and the medical management actions that should be taken by a healthcare provider.

---

Q: Does Sermion 30 interact with common cold or flu remedies?

A: Sermion 30 is part of the ergot derivative class of medicines. Due to its mechanism, official warnings advise caution when it is co-administered with other vasoconstrictive agents, which are frequently found in some cold and flu remedies.

---

Q: How long does Sermion 30 stay in your system after the last dose?

A: The drug and its primary active by-products are mostly eliminated from the body over a period of three to four days. This clearance process relies primarily on the function of the kidneys and the liver.

---

Q: What is the difference between Sermion 30 and its lower strength counterparts?

A: Sermion 30 mg is the higher strength tablet form available, whereas 10 mg tablets are also available. Official product information indicates that the higher strength is typically used in the continuation of treatment after the initial dose has been established and adjusted by a health professional.

How to Store and Dispose of Sermion 30

The storage and disposal of Sermion 30 mg film-coated tablets must align strictly with the rules documented in official regulatory labeling.

Official Storage Requirements

Requirement Category	Condition
Temperature	Does not require any special temperature storage conditions.
Packaging	Must be kept in the original container to maintain integrity and provide protection from moisture.
Child Safety	Keep out of the sight and reach of children as a mandatory safety requirement.

Disposal Instructions

Any unused or expired Sermion 30 mg product must be disposed of in accordance with local requirements. This instruction mandates that the medication should not be thrown into household waste or flushed into wastewater to protect the environment. The proper method involves returning the product to a pharmacy or designated collection point.